Rein Therapeutics Overview
- Year Founded
-
2001
- Status
-
Public
- Employees
-
10
- Stock Symbol
-
RNTX
- Investments
-
1
- Share Price
-
$0.36
- (As of Thursday Closing)
Rein Therapeutics General Information
Description
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
Contact Information
Website
www.reintx.comCorporate Office
- 12407 North Mopac Expressway
- Suite 250 Number 390
- Austin, TX 78758
- United States
Corporate Office
- 12407 North Mopac Expressway
- Suite 250 Number 390
- Austin, TX 78758
- United States
Rein Therapeutics Timeline
Rein Therapeutics Stock Performance
As of 19-Nov-2026, Rein Therapeutics’s stock price is $0.36. Its current market cap is $31.7M with 86.3M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.36 | $0.36 | $0.28 - $2.10 | $31.7M | 86.3M | 586K | -$1.51 |
Rein Therapeutics Financials Summary
As of 30-Sep-2026, Rein Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 73,717 | 71,449 | 77,185 | 2,826 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (50,429) | (50,582) | (64,364) | (15,957) |
| Net Income | (49,717) | (49,871) | (62,883) | (15,732) |
| Total Assets | 59,430 | 24,158 | 62,190 | 106,008 |
| Total Debt | 48 |
Rein Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Rein Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Rein Therapeutics Comparisons
Industry
Financing
Details
Rein Therapeutics Competitors (115)
One of Rein Therapeutics’s 115 competitors is Inovio Pharmaceuticals, a Corporation company based in Plymouth Meeting, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Phathom Pharmaceuticals | Formerly VC-backed | Florham Park, NJ | ||||
| XBiotech | Corporation | Austin, TX | ||||
| Zealand Pharma | Formerly VC-backed | Soborg, Denmark | ||||
| Xenetic Biosciences | Corporation | Framingham, MA |
Rein Therapeutics Patents
Rein Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4719450-A2 | Modified caveolin-1 peptide formulations and methods of manufacturing and use thereof | Pending | 30-May-2023 | ||
| AU-2023305611-A1 | Modified caveolin-1 peptide formulations and methods of manufacturing and use thereof | Pending | 12-Jul-2022 | ||
| EP-4554605-A2 | Modified caveolin-1 peptide formulations and methods of manufacturing and use thereof | Pending | 12-Jul-2022 | ||
| EP-4554605-A4 | Modified caveolin-1 peptide formulations and methods of manufacturing and use thereof | Pending | 12-Jul-2022 | ||
| AU-2022371643-A1 | Modified caveolin-1 peptides for the treatment of chronic kidney disease | Pending | 22-Oct-2021 | A61K38/177 |
Rein Therapeutics Signals
Rein Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Rein Therapeutics Acquisitions (1)
Rein Therapeutics’s most recent deal was a Merger/Acquisition with Lung Therapeutics. The deal was made on 31-Oct-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Lung Therapeutics | 31-Oct-2023 | Merger/Acquisition | Drug Discovery |
Rein Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
38.28 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Rein Therapeutics FAQs
-
When was Rein Therapeutics founded?
Rein Therapeutics was founded in 2001.
-
Where is Rein Therapeutics headquartered?
Rein Therapeutics is headquartered in Austin, TX.
-
What is the size of Rein Therapeutics?
Rein Therapeutics has 10 total employees.
-
What industry is Rein Therapeutics in?
Rein Therapeutics’s primary industry is Drug Discovery.
-
Is Rein Therapeutics a private or public company?
Rein Therapeutics is a Public company.
-
What is Rein Therapeutics’s stock symbol?
The ticker symbol for Rein Therapeutics is RNTX.
-
What is the current stock price of Rein Therapeutics?
As of 19-Nov-2026 the stock price of Rein Therapeutics is $0.36.
-
What is the current market cap of Rein Therapeutics?
The current market capitalization of Rein Therapeutics is $31.7M.
-
Who are Rein Therapeutics’s competitors?
Inovio Pharmaceuticals, Phathom Pharmaceuticals, XBiotech, Zealand Pharma, and Xenetic Biosciences are some of the 115 competitors of Rein Therapeutics.
-
What is Rein Therapeutics’s annual earnings per share (EPS)?
Rein Therapeutics’s EPS for 12 months was -$1.51.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process